PEDONCOVID - SFCE national cohort on SARS-CoV-2 (COVID-19) infections in paediatric oncology-haematology
Head :
ROUGER-GAUDICHON Jérémie
Last update : 05/05/2021 | Version : 1 | ID : 73865
| General | |
| Identification | |
| Detailed name | SFCE national cohort on SARS-CoV-2 (COVID-19) infections in paediatric oncology-haematology |
| Sign or acronym | PEDONCOVID |
| General Aspects | |
| Medical area |
Pediatrics |
| Study in connection with Covid-19 |
Yes |
| Pathology (details) | Paediatric oncology |
| Keywords | cancer; paediatrics; chemotherapy; SARS-CoV-2; COVID-19 |
| Scientific investigator(s) (Contact) | |
| Name of the director | ROUGER-GAUDICHON |
| Surname | Jérémie |
| Organization | CHU Caen Normandie |
| Collaborations | |
| Funding | |
| Governance of the database | |
| Sponsor(s) or organisation(s) responsible | CHU Caen Normandie |
| Organisation status |
Public |
| Additional contact | |
| Main features | |
| Type of database | |
| Type of database |
Study databases |
| Study databases (details) |
Cohort study |
| Database recruitment is carried out by an intermediary |
A selection of health institutions and services |
| Database recruitment is carried out as part of an interventional study |
No |
| Database objective | |
| Main objective | Describe the presentation and clinical course of SARS-CoV-2 infection among patients followed up in a paediatric oncology-haematology department or young adult and adolescent unit at an SFCE centre, for cancer or a benign tumour treated with chemotherapy, radiotherapy or targeted therapy. |
| Inclusion criteria |
Children and legal representatives, or adult patients having received information on the study
AND - Patient followed up in a paediatric oncology-haematology department or young adult and adolescent unit at an SFCE centre for cancer or a benign tumour treated with chemotherapy, radiotherapy or targeted therapy, with a cancer treatment either ongoing or completed within the past 6 months, or a history of allogeneic haematopoietic stem cell transplantation with immunosuppressant therapy ongoing or discontinued within the past 6 months, or a history of CAR-T cell therapy AND - Diagnosis of SARS-CoV-2 infection confirmed by PCR or positive IgM serology OR - Clinical and radiological diagnosis characteristic of SARS-CoV-2 infection without confirmation of infection by PCR or positive IgM serology with: o Presence of at least 2 of the following signs in the event of contact with a subject currently presenting SARS-CoV-2 positive infection, or 3 of the following signs in the absence of contact: fever, cough, dysgeusia, dysosmia, myalgia, chest pain, dyspnoea, signs of respiratory distress, rhinorrhoea or nasopharyngeal congestion, diarrhoea, headaches, recent onset or exacerbation of asthenia and rash. AND o One or more radiological abnormalities observed on chest CT scan compatible with a diagnosis of COVID-19: peripheral and/or subpleural and/or bilateral ground-glass opacities, intralobular thickening with a crazy-paving appearance, linear condensations with or without peripheral halo (reverse halo sign). |
| Population type | |
| Age |
Newborns (birth to 28 days) Infant (28 days to 2 years) Early childhood (2 to 5 years) Childhood (6 to 13 years) Adolescence (13 to 18 years) |
| Population covered |
Sick population |
| Pathology | II - Neoplasms |
| Gender |
Male Woman |
| Geography area |
National |
| Data collection | |
| Dates | |
| Size of the database | |
| Size of the database (number of individuals) |
< 500 individuals |
| Data | |
| Database activity |
Current data collection |
| Type of data collected |
Clinical data Biological data |
| Clinical data (detail) |
Direct physical measures |
| Presence of a biobank |
No |
| Procedures | |
| Followed pathology | |
| Promotion and access | |
| Promotion | |
| Access |
